Myriad Genetics Splits 2-for-1

Myriad Genetics (MYGN), one of my favorite mid-cap biotech stocks split 2-for-1 today. Shareholders now have twice as many shares and the stock price dropped in half, although the stock is up nicely today.

Myriad’s tests can determine a patient’s risk for cancer just by looking at their genes. What’s even more impressive, the company is also developing treatments for those diseases based on gene therapy and other high-tech procedures. Myriad’s drug candidates include a brain tumor therapy and blood cancer compound that could revolutionize the industry. I think we’re going to hear a lot more about Myriad in the years ahead.

In its latest quarter, Myriad’s earnings rose to $21.2 million or 43 cents per share, compared with a net loss of $5.1 million or 11 cents per share in the same quarter a year ago. During the same period, its sales rose 48.9% to $84.4 million compared to $56.7 million. In the past month, Wall Street has revised its consensus earnings estimate 22.3% higher, a great sign that we’re in store for future earnings surprises in this stock.

Myriad Genetics is an excellent buy.

More Louis Navellier

Twitter

Facebook

RSS Feed

Little Book

InvestorPlace Network

InvestorPlace.com